CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancers

So Jeong Lee, Cheong-Soo Hwang, Young-Keum Kim, Hyun Jung Lee, Sang-Jeong Ahn, Nari Shin, Jung Hee Lee, Dong Hoon Shin, Kyung Un Choi, Do Youn Park, Chang Hun Lee, Gi Young Huh, Mi Young Sol, Hee Jin Lee, Gyungyub Gong, Jee Yeon Kim, Ahrong Kim

Cancer Research and Treatment. 2017;49(2):313-321. Published online 2016 July 7 DOI: https://doi.org/10.4143/crt.2016.098

Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancers

Cancer Research and Treatment. 2017;49(2):313-321

Link1 Link2

Link3

Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer

Hiroaki Inoue, Rie Horii, Yoshinori Ito, Takuji Iwase, Shinji Ohno, Futoshi Akiyama

Breast Cancer. 2017;25(3):268-274

Link1 Link2

Link3

Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer

Tresa M. McGranahan, Alipi V. Bonm, Jennifer M. Specht, Vyshak Venur, Simon S. Lo

Cancers. 2022;14(20):5136

Link1

155P Artificial Intelligence (AI) - powered human epidermal growth factor receptor-2 (HER2) and tumor-infiltrating lymphocytes (TIL) analysis for HER2-positive early breast cancer patients treated with HER2-targeted neoadjuvant chemotherapy (NAC)

S.Y. Cho, Y. Lim, S.I. Cho, S. Kim, G. Park, S. Song, H. Song, S. Park, M. Ma, W. Jung, K. Paeng, C-Y. Ock, E.Y. Cho, S.Y. Song

Annals of Oncology. 2022;33:S610

Link1 Link2

Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration

Shuzhen Liu, William D Foulkes, Samuel Leung, Dongxia Gao, Sherman Lau, Zuzana Kos, Torsten O Nielsen

Breast Cancer Research. 2014;16(5):

Link1

Link2 Link3 Link4

Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature

Eirini Thanopoulou, Leila Khader, Morena Caira, Andrew Wardley, Johannes Ettl, Federica Miglietta, Patrick Neven, Valentina Guarneri

Cancers. 2020;12(11):3317

Link1

High Expression of NRF2 Is Associated with Increased Tumor-Infiltrating Lymphocytes and Cancer Immunity in ER-Positive/HER2-Negative Breast Cancer

Masanori Oshi, Fernando A. Angarita, Yoshihisa Tokumaru, Li Yan, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe

Cancers. 2020;12(12):3856

Link1

Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Co-expressing Tumors

Debora de Melo Gagliato, Jesus Soberino, Jose Manuel Perez-Garcia, Javier Cortes

Her2-Positive Breast Cancer. 2019;119-133

Link1 Link2

Dual Targeting of Human Epidermal Growth Factor Receptor 2 (HER2) in Neoadjuvant Trials for Operable HER2 Positive (HER2+) Disease

Komal Jhaveri, Chau Dang

Current Breast Cancer Reports. 2013;5(4):321-330

Link1

Link2 Link3

Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor–positive breast cancers

Uma Krishnamurti, Ceyda Sonmez Wetherilt, Jing Yang, Limin Peng, Xiaoxian Li

Human Pathology. 2017;64:7-12

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.